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25 Abstract
26 Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene 
27 during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis 
28 and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as 
29 a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration 
30 and angiogenesis. Several studies have investigated the role of midkine as a cancer biomarker for the detection,
31 prognosis, and management of cancer, as well as for monitoring the response to cancer treatment. Moreover, several
32 efforts are also being made to elucidate its underlying mechanisms in therapeutic resistance and immunomodulation 
33 within the tumor microenvironment. We hereby summarize the current knowledge on midkine expression and
34 function in cancer development and progression, and highlight its promising potential as a cancer biomarker and as a
35 future therapeutic target in personalized cancer medicine.
36
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1. Introduction
Midkine (MDK) is a heparin-binding growth factor first discovered as a highly expressed gene during mouse
embryogenesis [1]. To date, MDK is viewed as a multifunctional protein and along with pleiotrophin (PTN), they
form a structurally unique family of heparin-binding growth factors [2]. MDK is a soluble secreted protein that is
highly elevated in various diseases, such as cancer, and therefore it could serve as a valuable disease biomarker [3].
In many types of cancer, MDK has been shown to be overexpressed [3], especially during tumor progression into
more advanced stages [4]. Of note, MDK expression in tumors has been determined by blood [5, 6], urinary [7] and 
tumor analysis [8].
MDK is implicated in various physiological processes such as development, reproduction and repair thus
playing important roles in the pathogenesis of malignant and other diseases [9]. Therefore, this protein is expressed 
by a variety of cells under physiological and pathological conditions. Under physiological conditions significant
MDK expression is observed in the epidermis [10], bronchial epithelium [11] and lymphocytes [12, 13]. Contrarily,
in another study, MDKwas shown to be expressed in several tumor cell lines, but not in blood-derived normal cells, 
including monocytes, lymphocytes, or activated T lymphocytes)[14]. Consistent with its role during mouse
embryogenesis, MDK is expressed in embryonic stem cells and its role in their survival has been well documented
[15]. In particular, MDK is intensely expressed in the mid-gestation stage and from the mode of its distribution, has
been suggested to play roles in neurogenesis, epithelial-mesenchymal interactions and mesoderm remodeling [16, 
17]. Moreover, the mode of MDK location is consistent with its multiple roles in neurogenesis. MDK is strongly 
expressed in the basal layer of the cerebral cortex, which is rich in neural precursor cells, including neural stem cells
and also in radical glial processes, which are extensive neutral stem cells derived processes[18].
In spite of the roles of MDK in development mentioned above, MDK-deficient mice are born without 
major defects [19]. However, mice deficient in both genes MDK and PTN are born smaller in size, and about 50%
of them die before 4 weeks (see refs in [9]), suggesting that MDK and PTN potentially compensate for each other
during embryogenesis [9]. Furthermore, mice deficient in MDK or PTN exhibit a moderate auditory deficit, while
mice deficient in both present with more severe phenotype [20]. Moreover, mice deficient in MDK exhibit normal 
phenotypes in overall neural functions [19], although more in-depth analysis revealed deficits in specific neural
functions [21]. 
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Of note, MDK is strongly expressed by the majority of tumor cells in human malignant tumors [9, 22] and 
this will be the highlighted topic of the current review. As mentioned, MDK functions as a cytokine and growth 
factor with complex biological functions, and is implicated in a variety of (patho)physiological processes. [4]. MDK
is involved in the acquisition of multiple hallmarks of cancer: it promotes tumor cell proliferation, transformation
and epithelial to mesenchymal (EMT) transition [22-24]; it has angiogenic [25], mitogenic[26], antiapoptotic [27]
and anti-tumor immunity[28] roles, and it has also been involved in chemoresistance [29]. The wide expression of
MDK in many tumors, its causative involvement in cancer development and progression, as well as its potential role
as a cancer biomarker, are currently under investigation, because of the many potential translational applications, as
will be outlined below.
In this review, we offer a detailed insight on the functions and the molecular and biological significance of
MDK in cancer. Specifically, we provide an updated and critical viewpoint on the involvement of MDK in cancer 
progression and response to chemotherapy, as well as its emerging roles in antitumor immunity and inflammation.
Furthermore, we highlight and explore the significance of this protein as a tentative tumor biomarker in different
types of cancer, as well as its potential as a drug therapeutic target.
2. Genomic and protein domain organization of MDK 
The human MDK gene, located on 11q11.2 chromosome, encodes a 15.5-kDa protein rich in basic and cysteine
amino acids (UniProtKB - P21741 (MK_HUMAN)) [30-32].
In the promoter region of MDK, there are functional binding sites for retinoic acid receptor (RA) [33] and a
hypoxia responsive element, possibly involved in the increased expression of MDK in various tumors [34]. Hypoxia 
induces MDK expression through the binding of the hypoxia inducible factor 1a (HIF-1a) to a hypoxia responsive
element in MDK promoter [34]. There is also a binding site for the product of Wilms` tumor suppressor gene [35]
for MDK up-regulation in Wilm`s tumor cells [36]. Contrarily, MDK was shown to be downregulated by cortisol in 
fetal lung development via a glucocorticoid receptor action [37].
The MDK human gene consists of four coding exons. Due to the differential splicing and differences in the
transcription initiation site, there are seven isoforms in the MDK mRNA. Two isoforms are generated by skipping a 
coding exon and yield truncated MDK (Fig 1a). A truncated MDK variant derived from mRNA without the second 
coding exon is tumour-specific and might be of diagnostic value [9]. Different other truncated MDK (tMDK) 
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variants have also been reported in the literature. For instance, a truncated MDK variant (tMDKC) resulting from a 
deletion of part of exon 3 plus most of exon 4, encodes a putative 62 amino acid product [38]. Another variant
(tMDK) has also been identified in Wilms‟s tumour tissues [39] and in a variety of metastatic gastrointestinal
cancers. It remains to be elucidated whether such truncated variants play any role in a physiological, besides
neoplastic, context. Moreover, an isoform with two extended amino acids at the N-terminal is present in MDK (the
first two MDK residues (valine (V) and alanine (A)), called the „VA-MDK‟[40] (Fig 1a). Therefore these two forms
(the conventional MDK and the „VA-MDK‟) (Fig 1a) may occur simultaneously in vivo [40] and may have a
different biological significance. 
Mutations in MDK gene were not found in high frequency; a mutation was only found in lung cancer, 
cervical cancer and malignant melanoma patients respectively (http://www.oasis-genomics.org/, TCGA). Moreover, 
only 3 missense mutation types of unknown significance identified in lung cancer (lung squamous cell carcinoma
and lung adenocarcinoma) and 1 nonsense mutation in lung adenocarcinoma (cBioPortal for Cancer Genomics).
MDK protein contains a signal peptide for secretion (aa 1-20) and the main protein chain (aa 21-143) with
2 distinct domains (N-terminal and C-terminal domain) flanked by intra-domain with disulfide bridges [41] (Fig 1a). 
MDK and PTN share 50% sequence homology with cysteine and tryptophan residues being conserved in humans [9].
Among the two conserved MDK domains, the C-domain has been considered to play more important role in MDK
function, exerting neurite-promoting activity [22]. Moreover, two heparin-binding sites are present in the C-domain 
of human MDK [22]. The N-domain appears to be important for the stability of MDK as the C-terminal half of 
MDK is more susceptible to chymotrypsin digestion [42], involved in MDK dimerization [22]. Overall, further 
studies of the expression and function of MDK variants in health and disease are clearly warranted, and the relative 
expression levels of full-length versus MDK variants (for both gene and protein levels) (Fig 1a) might prove to be
diagnostically useful.
3. Implications of MDK in the hallmarks of cancer
MDK is a protein that initiates signaling through ligand-dependent receptor activation for a biological response [43].
To date, there have been key advances made on elucidating the functional MDK-mediated mechanisms, including 
diverse receptors and complicated intracellular signaling pathways. The glycosaminoglycan-recognizing activity of
MDK is important for this mechanism of action. For this reason, proteoglycans including receptor-like protein 
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tyrosine phosphatase- ζ (PTP-ζ)[44], syndecans [17], and glypican-2 [45], demonstrate a strong affinity for
MDK(Fig 1b). Other proteins, such as low-density lipoprotein receptor-related protein (LRP) [46], α4β1-integrin 
and α6β1-integrin [47] also serve as putative MDK receptors, which, together with PTP-ζ form a receptor complex 
for MDK binding (Fig 1b). In general, the interactions of MDK with the above mentioned receptors or receptor 
complexes promote cancer cell growth, migration, metastasis and angiogenesis [23] via the activation of 
downstream signaling cascades [44, 46] (Fig 1b).
As already explained, MDK is a growth factor overexpressed in various human malignancies, [43, 48], and the
downstream signaling events may be linked to a vast plethora of phenotypic characteristics leading to cancer
development and progression [25, 49-51] (Fig 1b). In this chapter, we describe the involvement of MDK in cancer-
related signaling from the viewpoint of the well-described hallmarks of cancer, as described by Hanahan and 
Weinberg [52] and indicated briefly as an illustration in Figure 2.
3.1. MDK-mediated proliferation/growth signaling, and apoptosis evasion 
Recent studies demonstrated that MDK binds to heparan sulfate and chondroitin sulfate and activates several 
signaling pathways contributing to cell growth and proliferation [9] via downstream signaling systems such as the
Src family kinases and the tyrosine phosphorylation of PI3-kinase and MAP kinases [46, 51] (Figure 2a).
Moreover, it was demonstrated that the resistance of glioma cells to tetrahydrocannabinol (THC) relies on 
the MDK-mediated stimulation of anaplastic lymphoma kinase (ALK), making the cells resistant to autophagy-
mediated cell death in vitro and in vivo [53, 54]. In particular MDK, modulates p8/TRB3 expression as well as the 
activity of the Akt/mTORC1 axis, via the ALK receptor, to prevent the autophagy-mediated cell death by THC
cannabinoids[55](Figure 2a). In vivo MDK silencing or ALK pharmacological inhibition sensitizes cannabinoid-
resistant tumors to THC antitumoral action [55], suggesting that MDK/ALK axis could be an efficient target for 
glioma therapies. Previous reports also suggested that anaplastic lymphoma kinase (ALK) is included in the receptor
complex of MDK along with LRP and integrins [9, 54]. In specific, after activation of the receptor complex by
MDK, ALK phosphorylates the insulin receptor substrate-1, and activates MAP kinase and PI3 kinase leading to 
transcriptional activation of nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB)[54] (Figure 2a). 
Taken together, MDK acts through diverse downstream signaling pathways, including, but not limited to, the Src 
and NF-κB to elicit pro-tumoral responses in many cancer types. Interestingly, MDK may also be implicated in
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survival pathways in hematopoietic malignancies. Foremost, MDK enhances the survival of mature B cells and the
suppression of MDK-dependent survival pathway might be considered for treatment of B cell malignancies [56].
3.2. MDK-mediated angiogenesis
Of note, the tumor growth-promoting activity of MDK is also partially due to its ability to promote tumor
angiogenesis. MDK, apart from a heparin-binding cytokine or a cancer cell growth factor, is also a potent pro-
angiogenic factor [57, 58]. Enhanced tumor growth after subcutaneous injection of MDK into nude mice was in part
associated with increased microvessel density, indicating enhanced proliferation of endothelial cells within the
tumor [25] (Figure 2b). Interestingly, high MDK expression was localized in tumor endothelial cells of human 
neural tumor tissues, suggesting that endothelial cells also can represent the source of MDK during tumor 
angiogenesis [59]. In addition, conditioned media of cancer cells, artificially induced to overexpress MDK has been
shown to induce angiogenesis by promoting proliferation of endothelial cells in vitro [58]. Antisense
oligonucleotides against MDK inhibited growth of endothelial cells in vitro and tumor-induced angiogenesis in a
chorioallantoic membrane (CAM) assay and tumor vascularization in vivo [60]. Mechanistically, MDK seems to
control plasma bioavailability of vascular endothelial growth factor-A (VEGFA), which in turn, is related to the
expression of neuronal nitric oxide synthase (Nos1) and endothelial Nos (Nos3) in endothelial cells, and eventually 
angiogenesis [61] (Figure 2b).
Although speculative, there is now a compelling line of evidence suggesting that MDK could be involved 
in hypoxia-mediated tumor angiogenesis: i) hypoxia induces MDK expression through the binding of hypoxia 
inducible factor-1a (HIF-1a) to a hypoxia responsive element on the MDK promoter [34], ii) MDK was also shown 
to be implicated in hypoxia-induced angiogenesis in non-neoplastic contexts such as ischemia of adult normal 
tissues [62], iii) hypoxia increases MDK protein levels in human polymorphonuclear neutrophils (PMN), monocytes, 
and human umbilical vein endothelial cells (HUVECs) [62] and iv) as already mentioned, the tumor growth 
promoting activity of MDK has been found to be due to its ability to promote tumor angiogenesis [58]. The precise 
mechanistic underpinnings remain to be elucidated.
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3.3. MDK-mediated cancer invasion and metastasis
MDK has been proposed to mediate metastasis by its combined mitogenic, pro-inflammatory and 
angiogenic functions [4, 63, 64]. Of note, MDK has been linked to epithelial-to mesenchymal transition EMT [65]
(Figure 2c, i). For instance, MDK, has been described to be linked to EMT [66]; and to interact with various 
protein members of the TGF-β pathway in vitro [65], a central mediator pathway for EMT [67], thus leading to
increased migration of cancer cells in vitro and in vivo[66]. Additionally, MDK was described to mediate cell
survival and growth mainly through PI3K and extracellular signal-regulated kinase (ERK) signaling [68, 69]. 
However, the expression of cell-cell and cell-matrix adhesion molecules ICAM-1, E-cadherin, periostin and MDK
was not significantly linked to metastatic disease in pancreatic ductal adenocarcinomas (PDACs) cells [65]. 
Furthermore, estrogen enhanced MDK expression in accordance with an increase of EMT, whereas knockdown of
MDK blocked EMT under estrogen stimulation in lung adenocarcinoma, indicating a pivotal role of MDK in 
progression of estrogen-regulated EMT [70]. After ligand-receptor interactions of PTPζ with MDK, tyrosine
phosphorylation was increased in cytoplasmic signaling molecules, such as β-catenin [71, 72]. Dephosphorylation of 
β-catenin is a critical step in the canonical Wnt signaling. In normal osteoblasts, MDK has been shown to inhibit
osteoblast proliferation by interfering in Wnt signaling via inhibition of the PTPζ-mediated dephosphorylation of β-
catenin [71]. In glioma development, the Wnt/β-catenin/MDK molecular network as control mechanism was further
revealed. It was found that Wnt3a administration or transfection of a constitutively activated β-catenin promoted 
MDK expression in glioma cells [73]. Furthermore, a TCF/LEF binding site was identified, with which beta-catenin 
interacts, on the proximal promoter region of MDK gene [73].
In another study, an interaction between the Notch-2 receptor and MDK (Figure 2c, i), in pancreatic 
ductal adenocarcinoma (PDAC) cells activated Notch signaling, induced EMTupregulated NF-kB, and increased
chemoresistance in a downstream sequence [74].The interaction of Notch2 and MDK was observed in vitro,
with the treatment of Notch-2–positive PDAC cells with soluble MDK resulting in Notch-2 activation and
linked to upregulation of Notch downstream targets (Hes-1 and NF-kB/RelA) [74]. Similarly, it was also
demonstrated that MDK binds to the Notch2 receptor in HaCaT, thus activating Notch2 signaling and leading to a 
8
 
 
   
     
        
    
        
        
       
      
        
      
   
          
         
     
      
         
       
     
  
    
   
       
        
         
    
           
      
    
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
MDK-induced cross talk of Notch2/Jak2/Stat3 signaling pathways that regulate cell plasticity and motility 
contributing to EMT, as well as to later stages of tumorigenesis [75].
Proteolytic enzyme networks may also participate in MDK-induced metastasis [76, 77] (Figure 2c, ii). 
Interestingly, kallikrein-related peptidases (KLKs), the largest family of extracellular serine peptidases known to-
date [78], may play a leading role in the regulation of the cell-biological programs, facilitating cancer progression, 
particularly through extracellular hydrolysis of crucial mediators such as cell-cell adhesion proteins, membrane-
bound proteins and receptors, cytokines and growth factors, ECM proteins, as well as other KLKs [78]. MDK was
identified as a key substrate for the two chymotrypsin KLKs (KLK7 and KLK9) [76, 77] upon specific cleavage,
suggesting a potential role of the KLK7/9-MDK axis in cancer progression and metastasis, especially in tumors with
aberrant deregulation of KLK7/9 expression [79, 80]. Future studies should investigate the exact roles of 
extracellular proteolytic networks in MDK cleavage regulation and MDK-driven metastasis.
A pro-metastatic role of MDK in melanoma progression was based on its link to neolymphangiogenesis via
the mTOR signaling pathway [81] (Figure 2c, iii). MDK binds heparan sulfate and lymphatic endothelial cells
(LECs), thus activating mTOR signaling to increase the expression of VEGFR3, through which major
lymphangiogenic signals are transduced [81]. These signals stimulate the systemic lymphangiogenesis and tumor
cell transmigration through the lymphatic endothelium in pre-metastatic sites (Figure 2c, iii). As expected, the
silencing of MDK decreased lymphangiogenesis and metastasis in lymph nodes and lungs, while MDK
overexpression caused the opposite effect in immunodeficient nu/nu mice [81].
3.4. MDK-mediated anti-tumor immunity and inflammatory response
3.4.1. Involvement of MDK in anti-tumor immunity
The emerging appreciation of the MDK function in the immune system has been assessed, by sculpting myeloid 
cell phenotype and driving immune cell chemotaxis [14] (Figure 2d). In addition, it has been shown that in vitro
stimulation of CD8+ T cells collected from HLA-A2 healthy donors and immunization of HLA-A2 transgenic
mice, identified two CD8+ T cell epitopes, which demonstrate that MDK-specific cytotoxic T lymphocytes can 
lyse tumor cells [14] (Figure 2d). One of these CD8+ T cell epitopes resides in the signal peptide, as described
previously for other secreted tumor antigens [82], suggesting that MDK could be a novel candidate for cancer
vaccine development. Moreover, the capacity of MDK to prime CD4+ T lymphocytes in humans and localized 
9
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several CD4+ T cell epitopes of MDK-restricted to different HLA-DR molecules was also identified [28]. Two 
CD4+ T cell epitopes, overlapping MDK signal peptide but differing in their processing outcome in tumor cells, 
were responsible for a large proportion of the T cell response [28]. 
3.4.2 MDK-mediated tumor promoting inflammation
MDK is one of the growth factors that modulate inflammation [83], in part due to presenting similar properties
with antibacterial proteins triggering the activation of the innate immune system [84]. MDK expression is strongly
induced during inflammatory processes [85], leading to increased angiogenesis. Neutrophils, which also play a 
role in angiogenesis [86], have a designated role in MDK-mediated inflammation. MDK seems to support the
polymorphonuclear neutrophil (PMN) adhesion by promoting high affinity of β2-integrins, thereby facilitating
PMN trafficking during acute inflammation (Figure 2e). The suppression/blocking of low-density lipoprotein 
receptor-related protein 1 (LRP1) suggested that it may act as a receptor for MDK on PMNs [87] (Figure 2e).
Besides neutrophils, MDK also regulates macrophage chemotaxis [85] and MDK-deficient mice displayed lower
neutrophil and macrophage numbers in a model of early-stage of fracture healing [88]. The important role for the
pro-inflammatory cytokines MDK and IL-6 in the response to fracture in estrogen-deficient mice was also 
assessed [89], and demonstrated increased MDK levels after fracture in mice and female fracture patients after
menopause. Given the above, the role of MDK in the neutrophil and macrophage-mediated inflammatory 
responses in cancer need to be confirmed and elucidated. In this context, the potential pharmacological targeting 
of MDK as a potential anti-inflammatory therapy should also be assessed. 
4. MDK as a diagnostic and prognostic cancer biomarker
MDK overexpression at the gene and the protein level within the tumour is a typical feature of cancer and has been 
reported for several different cancer types [90-93]. As a plasma-secreted protein, MDK has also been found
increased in the blood and urine of patients with malignant tumors [94, 95]. Although there are studies showing lack 
of association between MDK plasma levels and diagnostic accuracy or prognostic significance (i.e endometrial
cancer)[96], MDK has been reported as a potential diagnostic and prognostic cancer biomarker associated with poor 
survival [97, 98]. Because it is not cancer-specific, but related to the tumorigenic process as described above, MDK 
may be considered as multi-cancer biomarker. Since there is an urgent need for the discovery of novel tumor
10
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biomarkers, here, we detail the potential of MDK as a cancer biomarker, and its role in prognosis and/or diagnosis in 
certain types of cancer (Table 1).
4.1. Pancreatic Cancer
Pancreatic cancer is one of the most aggressive human malignant cancers associated with rapid progression and poor
prognosis [99]. Insufficient diagnostic tools and therapeutic options for pancreatic ductal adenocarcinoma (PDAC)
still substantiate its ranking as fourth leading cause of cancer-related death. Therefore, a better understanding of
newly identified and cancer-specific key molecules that could serve as novel diagnostic and prognostic tumor 
markers for PDAC are needed. Foremost, MDK mRNA was found to be overexpressed in pancreatic cancer tissues
compared to normal tissues, suggesting that MDK is an early-disturbed molecule in the course of pancreatic 
neoplasmatogenesis [100]. Importantly, serum MDK concentrations were found significantly elevated in patients
with PDAC compared with healthy individuals [101], suggesting a potential role of MDK as a diagnostic marker for 
PDAC.
4.2. Lung cancer
Lung cancer is the leading cause of cancer-related mortality worldwide [102]. The incidence of non-small cell lung 
cancer (NSCLC), a major form of lung cancer, has increased in the past several decades. Early stage detection of
lung cancer is a key aspect that may offer more treatment options and a greater chance of survival to patients. MDK 
is one of the six-biomarker blood test for the detection of early stage lung cancer at risk populations [3]. A 
significant association was observed between overexpressed MDK (mRNA and protein levels) with malignant status
and poor prognosis in NSCLC patients [103]. MDK levels were found to be useful, minimally invasive biomarkers 
for NSCLC detection and prognosis [104].
4.3. Bladder cancer
Bladder cancer (BCa) is the most common malignancy of the urinary tract in the elderly population and the sixth 
most common cancer in men worldwide [105]. Although a great effort was performed to investigate putative urinary
biomarkers suitable for the non-invasive diagnosis of BCa, a routine application of these tests is not recommended 
for the primary detection of BCa [106]. MDK protein expression in BCa and its correlation with a poor outcome in
invasive bladder carcinomas has been reported [107], and increased MDK protein levels in urine specimens from
11
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292 BCa patients [7, 108, 109] was demonstrated. Importantly, the correlation between MDK protein concentration in 
293 urine and disease progression in terms of tumor stage and grade has been previously investigated [108]. MDK 
294 protein showed a substantial elevation in the urine of patients, although not in the urine of those with early-stage
low-grade tumours [108]. In another study, increased MDK levels were normalized to urinary creatinine, indicating 
296 that MDK may potentially be suitable marker for the identification of patients with high risk BCa [110].
297
298 4.4. Liver cancer
299 Hepatocellular carcinoma (HCC) is a common primary liver cancer and one of the most aggressive cancers
worldwide [111]. Early diagnosis has been considered as the most important factor to achieve long-term survival for
301 HCC patients [112] and the emergence of novel specific and sensitive biomarkers is essential. MDK mRNA levels
302 were higher in HCC specimens than in non-cancerous tissues [113] as well as serum MDK protein levels [94] and 
303 IHC analysis showed high MDK expression in HCC patients [114]. Of note, the diagnostic signature approach using 
304 a combined score of MDK with other 4 biomarkers rather than a single one, may improve the prediction accuracy of
the HCC patients [113] and the MDK levels in HCC with intra-hepatic metastasis were significantly higher than 
306 without [115]. MDK increased the diagnostic yield in alpha-fetoprotein (AFP)-negative HCC and had greater 
307 diagnostic performance than AFP, osteopontin (OPN) and dickkopf-1 (DKK-1) in the diagnosis of nonalcoholic 
308 steatohepatitis-HCC (NASH-HCC), thus playing a promising role in the asymptomatic diagnosis of HCC [116].
309
4.5. Melanoma
311 Melanoma is the most deadly type of skin cancer because of its early spread via the lymphatic vessels into lymph
312 nodes and distant organs [117]. Cutaneous melanoma is a type of cancer with an inherent potential for lymph node
313 colonization, which is generally preceded by neolymphangiogenesis [117, 118]. The question whether tumor
314 lymphangiogenesis occurs in human malignant melanomas of the skin and whether the extent of tumor
lymphangiogenesis is related to the risk for lymph node metastasis and to patient survival has been highly challenging
316 to answer. Analysis of the melanoma secreted proteome in cell lines and validation in clinical specimens, showed that 
317 MDK is a systematic inducer of neo-lymphangiogenesis that defines melanoma patient prognosis [81, 117]. More
318 specifically, an independent series of sentinel lymph node analysis from patients with stage II–III melanoma showed 
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that patients with high nodal MDK expression had significantly worse disease-free survival (DFS) than patients with
low nodal MDK expression
4.6. Brain tumors
Brain neoplasms are highly fatal and gliomas (including astrocytomas and the highest grade glioblastoma) are the most 
common type of primary malignant brain tumor. Gliomas are common primary brain tumors with poor outcome 
despite the strong treatment trials [119]. Since the clinical outcome is poor, the identification of new biomarkers for
improving prognosis is highly important. Previous reports showed that increased levels of MDK expression correlate
with the progression of human astrocytomas [120]. MDK over-expression was significantly correlated to poor survival
outcome in high-grade stage of human gliomas [119]. Moreover, the co-expression of MDK and PTN correlates with 
poor survival in glioma patients, suggesting that they may be used as both early diagnostic and independent prognostic 
markers [121].
4.7. Esophageal Cancer
The 5-year survival rate of esophageal cancer is less than 10% in developing countries, and more than 90% of these
cancers are squamous cell carcinomas (ESCC) [122]. Early detection is associated with improved survival in ESCC, 
therefore, there is a necessity for novel biomarkers to guide therapeutic management. MDK has been found to be 
over-expressed in various human esophageal malignant tumors [123, 124]. The expression of MDK was correlated
with poor tumor cell differentiation (poorly differentiated tumor cells-weak MDK expression) in ESCC [125]. High
serum MDK levels were associated with tumor size, immunoreactivity and poor survival in patients with esophageal
cancer [126]. 
4.8. Breast Cancer
Breast cancer is a complex genetic and highly prevalent disease and although several biomarkers have been 
extensively studied, only few have been approved for clinical use [127]. Different subtypes of breast cancer show 
diverse clinical outcome and may have different prognosis. Nowadays, there is still an urgent need to explore novel 
molecular targets that serve as prognostic biomarkers and novel therapeutic targets. Foremost, plasma and tissue
13
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MDK levels measurements in breast cancer patients were found abnormally elevated compared to healthy individuals 
[128, 129], suggesting that MDK is disturbed early on in the course of disease progression. Moreover, increased
plasma MDK levels in combination with conventional markers (such as CA15-3, CEA, and NCC‐ST435) provided 
significant improvement for breast cancer diagnosis [128]. Furthermore, increased MDK levels were correlated with 
menopausal status and nuclear grade in primary invasive breast cancer without distant metastasis [128]. Although
promising, the clinical significance of MDK in the plasma of breast cancer patients needs further exploration.
4.9. Ovarian Cancer
Ovarian cancer is the 8th most common cancer in women and the 2nd most common type of gynecological cancer in
the world [130]. The development of more accurate and “early detection” tests for ovarian cancer are undoubtedly 
the top priority for reducing mortality. A prior study has confirmed the utility of both MDK and anterior gradient 2 
(AGR2) proteins as plasma biomarkers for ovarian cancer and, when combined in a multi-analyte panel (consisting 
of MDK, AGR2 and CA125), it was shown these two proteins to significantly improve the diagnostic efficiency of 
CA125 [131].
5. The role of MDK as a predictive cancer biomarker in chemotherapy
Accumulating evidence indicates that MDK plays an important role as a drug-resistance regulatory factor. For 
example, it was previously demonstrated that MDK protects cancer cells against cannabinoid and doxorubicin
treatment [55, 132, 133]. Furthermore, MDK was overexpressed in drug-resistant gastric cancer cell sub-lines
compared with the parental drug-sensitive ones [134]. Contrarily, other studies indicate that MDK downregulation
induces cisplatin resistance in oral squamous [135] and renal carcinomas [136]. These observations collectively 
suggest that MDK may potentially induce either a drug-resistant or a drug-sensitive cancer cell phenotype,
depending on the context.
Several studies merely focused on the effect of MDK expression in tumour microenvironment cells on 
chemoresistance via different mechanisms. For example, it has been shown that MDK activated the Akt signaling 
pathway that provides cytoprotective signals to doxorubicin [137], as opposed to the MDK-sensitized ovarian cancer 
cells to paclitaxel and/or cisplatin [138]. In another study, it was demonstrated that the cytotoxic effect of cisplatin 
on the human gastric cancer cell line AGS was attenuated by recombinant human MDK, and was promoted by 
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suppressing MDK through downregulation of Notch pathway ligands and receptors [139]. Ovarian cancer cell lines 
376 expressing MDK levels were also used to detect drug cytotoxicity in vitro [138]; MDK could inhibit the expression
377 of the multidrug resistance-associated protein 3 (MRP3) and as such, enhanced the cytotoxicity of paclitaxel and/or
378 cisplatin [138]. MDK was also shown to have cytoprotective effect against cell-damaging effects of cisplatin, in part
379 through the enhancement of Bcl-2 expression in Wilms‟ tumor [36]. Moreover, investigating the role of MDK in the 
interplay between stromal cells and tumour cells, it was found that cancer-associated fibroblasts (CAFs) in the tumor
381 microenvironment (TME) contribute to high MDK levels in tumours and that CAF-derived MDK can promote 
382 cisplatin resistance [140]. In another study, Hu et al (2010) found that MDK expression causes increased efflux of 
383 chemotherapeutic drugs in lymphoblastic leukemia cells [141].
384 Overall, it appears that MDK may protect cancer cells from the cytotoxic effects of chemotherapy
(chemoresistance), however in some cases enhance the chemosensitivity, depending on the drug/tumor type
386 combination. It is crucial to understand the molecular mechanisms that drive the MDK-induced chemotherapeutic
387 agent resistance and/or chemosensitivity as they may aid the introduction of new therapies in cancer.
388
389 6. Strategies for MDK-mediated therapeutics in cancer
A growing body of evidence, including evidence described in the current review, has demonstrated that MDK is a
391 promising candidate as a therapeutic target for many human carcinomas [64]. MDK inhibitors including antibodies, 
392 aptamers, glycosaminoglycans, peptides and low molecular weight compounds, are currently under pre-clinical
393 development [18]. MDK inhibition was found to induce apoptosis [142] and suppress tumor growth and metastasis
394 [143]. Indeed, MDK gene knockdown by siRNA significantly induced apoptosis, while rec-MDK increased cell
proliferation in osteosarcoma [143]. Along the same study, inhibition of MDK-mediated signaling by anti-MDK 
396 monoclonal antibody (anti-MDK mAb) suppressed the in vitro and in vivo growth in osteosarcoma [143]. Moreover,
397 (siRNA)-mediated inhibition of MDK expression and antisense MDK oligodeoxyribonucleotides had antitumor
398 activity [144, 145].
399 Other trials suggested a MDK promoter-based conditionally replicative adenovirus therapy for tumors
highly expressing MDK [146-148]. An oncolytic adenovirus was engineered, whose replication is under the control
401 of the MDK promoter, to inhibit the growth of glioblastoma xenografts [18]. Interestingly, there is also a great
15
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402 interest in the discovery of synthesized tetrasaccharide derivatives following the glycosaminoglycan (GAG)-related 
403 sequence GlcNAc-β(1 → 4)-Glc-β(1 → 3) that strongly interact with the heparin-binding growth factor MDK [149]. 
404 MDK has also demonstrated synergism with natural compounds with anti-cancer properties. In ovarian
cancer, combined treatment of Dihydroartemisinin (DHA) and Curcumin (Cur) synergistically exhibited prominent 
406 anti-tumor activity via attenuation of MDK expression [150]. In another study, targeting MDK siRNA and quercetin
407 administration synergistically reduced the cell survival, induced apoptosis and caused G1 phase cell cycle arrest
408 more effectively than the individual therapy [151]. 
409 There are different MDK-mediated pathways that affect chemoresistsance. MDK upregulation has been 
linked to the failure of cancer therapies such as chemotherapy [134]. Several studies indicate the secretion and 
411 overexpression of MDK in drug‑ resistant cells [55, 152] and as such, targeting MDK could provide a new
412 therapeutic approach for treating MDK-expressing tumors [142]. By inhibiting/blocking the MDK mode of action 
413 prior to, or during, chemotherapy may force chemoresistant cells to revert to sensitive cells and may thus provide a 
414 tremendous benefit to patients with advanced cancers not responding to conventional treatments. Interestingly, the 
relationship between MDK expression, tumor response and chemotherapy response is complex and may depend 
416 upon tumor type, disease etiology and may also be stage-specific.
417 Overall, patient outcome can be improved with the future development of novel therapies interfering with
418 identified MDK signaling pathways or the mechanisms of MDK-mediated chemoresistance (i.e interference of the
419 MDK-mediated expression that regulates drug efflux upstream of the p-glycoprotein (P-gp) and the other transporter
proteins in lymphoblastic leukemia cells)[141]. Novel therapies applied with MDK inhibitors can serve in a more
421 selective and less cytotoxic manner with maximum efficiency and without resistance and/or recurrence. In future 
422 trials we anticipate that, combined treatment of MDK inhibitors or mAbs with chemotherapeutic drugs and not 
423 single drug treatment, may cause significant tumor retardation without side-effects in xenograft nude mice tumor
424 model and clinical trials as a safe therapeutic regimen. Since mice lacking the MDK gene are viable [20, 142], 
targeting MDK with novel inhibitors is an attractive therapeutic approach, because its inhibition is unlikely to have
426 systemic deleterious effects. Although further studies are needed, including identification of MDK direct targets,
427 additional structural modification and safety validation, MDK inhibitors look promising therapeutic targets for the
428 treatment of several cancers.
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429 Although MDK has been suggested as a potential, novel therapeutic drug for cancer therapy, we cannot 
exclude the role that the tumor microenvironment may play in obfuscating therapeutic efficacy, especially in highly
431 desmoplastic tumors such as in the highly-fibrotic cancers (i.e in pancreatic cancer, in which MDK has been 
432 suggested to play a role in invasion and metastasis) [65]. Collagen accumulation in desmoplastic pancreatic cancer 
433 could be a profound obstacle for the delivery of drugs targeting MDK (i.e MDK inhibitors or mAbs etc). Novel 
434 technologies aiming at improved drug delivery methods (i.e nanoparticles etc)[154] will be paramount in solving
these issues.
436 Overall, MDK could represent a promising molecular target for cancer therapy, therefore, it is important to
437 explore the implicated regulatory MDK-mediated mechanisms in cancer progression and metastasis.
438
439 7. Future Perspectives 
In this review we have summarized the multiple biological functions of MDK, a heparin-binding growth factor and
441 cytokine frequently upregulated in many malignancies, strongly suggesting its involvement in cancer development
442 and progression, and further delineating its role as a cancer biomarker and a novel therapeutic target. 
443 We reviewed here that a large number of studies have demonstrated higher MDK expression in malignant 
444 tissues [3]. The main advantage regarding the applicability of MDK in clinical practice is that it is a soluble cytokine,
which is easily measurable in the peripheral circulation, making it a relatively convenient and non-invasive
446 biomarker [3]. Its potential role as a tumor biomarker constitutes MDK a sound target for diagnostic tests measuring 
447 circulating growth factors, and indeed, such MDK tests are currently tested in the clinic. MDK has already been 
448 shown to significantly improve detection, management and treatment of cancer, and there is significant promise for 
449 developing further MDK-based diagnostics in the future. However, there is also a prominent disadvantage in this
landscape: the lack of specificity. To overcome this issue, a number of studies have combined MDK with other 
451 biomarkers (multi-analyte biomarker panel), suggesting that this approach could outperform other current serum
452 biomarkers for early detection of malignancies. In any case, large cohort analyses have not yet performed to evaluate 
453 the utility of MDK as a cancer biomarker in any of the aforementioned contexts.
454 The mechanism by which MDK induces tumorigenesis has been related to cancer cell proliferation,
survival, anti-apoptosis, angiogenesis, and EMT-regulation [22, 23]. MDK functions are mediated mainly through 
17
 
 
        
      
     
          
   
     
     
  
  
       
        
    
    
     
      
    
        
     
       
  
        
      
          
   
 
      
     
    
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
specific receptor binding, which triggers well-known downstream signaling pathways implicated in tumor growth 
and metastasis, such as the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt,
and extracellular signal-regulated kinase 1/2 (ERK 1/2) [22, 23]. Importantly, melanoma metastasis was one of the 
highlighted topics in a recent study by Olmeda et al. (2017), describing that the top candidate mediator of melanoma
lymphangiogenesis and metastasis was MDK, underscoring its potential as a therapeutic target in melanoma
metastasis [81]. Moreover, MDK is an angiogenic factor that mainly promotes tumor growth and progression [25], 
although the exact mechanisms of MDK-mediated angiogenesis need to be further elucidated. The delineation of the 
MDK-mediated angiogenesis mechanisms along with the development of MDK inhibitors as anti-angiogenic 
therapeutic aspects is highly recommended.
Several studies focus merely on tumour-derived MDK-mediated chemoresistance in both an autocrine- and 
stromal-mediated paracrine-derived manner [132, 140]. However, the role of MDK in drug resistance has remained
largely elusive, underscoring the need to explore the potential MDK-mediated mechanisms underlying 
chemoresistance and/or chemosensitivity in order to enhance its effect and prolong patient survival.
We have also examined recent observations of MDK serving as a therapeutic target for certain human
carcinomas. A better understanding of the MDK-mediated signaling pathways may open up novel therapeutic 
strategies for a large number of cancer subtypes. Conditional transgenic mice using CRISPR-Cas9 technology and 
newly identified MDK inhibitors will constitute novel and powerful tools towards this cause. An alternative 
therapeutic method could be the inhibition of MDK-cell surface receptors interaction with novel lead compounds.
The wealth of novel small molecule inhibitors that have, or will be, successfully developed against MDK and/or its
receptors, substantiates MDK as an attractive drug target in cancer.
Because of its wide expression in cancer tissues and its contribution to tumorigenesis, MDK can be
considered as a tumor-shared antigen and appears to be an attractive cancer vaccine candidate. MDK-based 
vaccination using peptides, DNA, the whole protein, or viral vectors could be applied to patients who have a 
significant level of MDK in their body fluids [14]. 
Immune checkpoint blockade (ICB) immunotherapy employs antibody-targeting of specific inhibitory 
receptors and ligands, such as cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), programmed cell death 
protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1)[155]. For instance one of the common
immunotherapeutic drugs (Pembrolizumab) is a humanized monoclonal antibody targeting PD-1 and has been 
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approved for the treatment of many primaries including, unresectable or metastatic melanomas[156] metastatic non-
small cell lung cancer (NSCLC) [157], advanced urothelial cancer [158] and against any unresectable or metastatic
solid tumor with DNA mismatch repair deficiency or a microsatellite instability-high state or colon cancer that 
exhibits progression under treatment (FDA approval, May 2017). Since MDK is a pan-cancer biomarker expressed 
in a wide range of cancer tissues, it could serve as a predictive biomarker for the likelihood of a patient responding
favorably to therapy or developing toxicity, and allow for the monitoring of their therapeutic outcome. Therefore,
MDK as a secreted protein could be served as a routinely available blood or urine biomarker that may have shown 
promise in predicting immunotherapy response. Moreover, evaluated and highly specific MDK monoclonal 
antibodies could be used in combination with the already recommended immune checkpoint inhibitors (i.e PD1/PD-
L1) (i.e Pembrolizumab monoclonal antibody) that may improve the therapeutic efficiency and the clinical outcome
of cancer patients.
New and exciting findings in the MDK field are now beginning to emerge, however a lot is still to be
achieved, and several questions remain unanswered: i) what is the relative functional contribution of the different 
MDK forms in cancer progression?, ii) are there specific MDK mutations that correlate its expression with cancer
disease progression?, iii) what type of inhibitors should we develop for compatible clinical trials and would these
inhibitors be promising therapeutic targets in personalized medicine? Many challenges lie ahead before our
complete understanding on the MDK-related network, contributing to MDK-driven cancer tumorigenesis and
response to therapy.
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1135 Figure legends
1136
Figure 1. Structural domain organization and candidate receptors of MDK protein.
(a) MDK isoforms and splice variants. The conventional and „VA-MDK‟ variants differing in the N-terminal 
sequence in two amino acids [(the first two MDK residues (valine(V) and alanine(A)], as well as truncated MDK 
forms, are displayed in a comparative manner. The protein domain organization of MDK according to Uniprot
Database [UniProtKB - P21741 (MK_HUMAN)], is shown in the bottom half of the panel. MDK is a secreted 
protein of 15.5 kDa containing a signal peptide for secretion (aa 1-20) and the main protein chain (aa 21-143),
composed of two domains (N-Domain and C-Domain) held together by disulfide linkages. The C-terminal located 
domain is responsible for midkine activity and the N-terminal domain is required for dimerization [2]. (b) MDK
interactions with different plasma membrane receptors, including syndecans, integrins, protein tyrosine phosphatase 
ζ (PTPζ), anaplastic lymphoma kinase (ALK), low-density lipoprotein (LDL)-receptor-related protein (LRP) and
Notch2 receptor. All (or some) of these receptors could function as a multi-molecular complex coordinated to 
transduce the MDK signal into the cell by different signaling pathways, thus regulating different cancer related 
phenotypes.
Figure 2. Implications of MDK in the hallmarks of cancer.
(a) MDK-mediated proliferation/growth signaling through conventional intracellular circuitries and pathways
(Src/MAPK/PI3K; akt/mTORC1/NF-kappaB), (b) MDK involvement in angiogenesis and microvascular density 
through conventional cancer-associated angiogenic pathways, (c) MDK-mediated regulation of cancer cell 
invasion and metastasis via at least three disparate mechanisms: i) epithelial-to-mesenchymal (EMT) transition, ii) 
extracellular proteolytic relationships with kallikrein-related peptidases (KLKs) in the tumor microenvironment, iii) 
MDK-driven neolymphangiogenesis via mTOR signaling pathway activation and increased VEGFR3 
expression, (d) MDK involvement in anti-tumor immunity. MDK-specific cytotoxic T lymphocytes can lyse tumor
cells. (e) MDK-dependent immune cell chemotaxis: Neutrophil/macrophage adhesion and chemotaxis is mediated 
via an LRP1/β2-integrin signaling interplay that facilitates their trafficking during cancer-associated acute
inflammation.
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1164
1165 Table 1. The role of MDK as a diagnostic and prognostic biomarker in different types of cancer.
1166
Cancer MDK Diagnostic Prognostic Reference
type overexpression
(mRNA/protein)
Blood Tissue Urine
MDK/Cancer type Pancreatic + + - + - [100, 101]
Lung + + + + + [3, 103, 104]
Bladder - + + + + [107-110]
Liver + + - + - [113-116]
Melanoma - + - - + [81, 117]
Brain + + - + + [119-121]
Esophageal    + + - - + [123-126]
Breast + + - + + [128, 129]
Ovarian + + - + - [131]
1167
1168
1169
1170
1171
1172
1173
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